Come Wednesday afternoon investors of Generex Biotechnology Corporation had better have heard some valid updates from the company after the 1PM conference planned to take place at the Nasdaq HQ in Times Square, New York City.
The company issued two press releases last week announcing the event, making it doubly important that some valid news comes from it.
GNBT has been trickling downwards over the past few months following an autumn filled with chaos, but closed last week up over thirty percent after a Friday trading session that saw a thirteen percent increase on about two and a half times the normal daily trading average.
Hyped-up conference at the Nasdaq or not, last week showed that there is still interest in Generex, even without the Oral-lyn news that investors have long been waiting for.
The recent troubles at Mannkind could have Generex sitting in the driver's seat in terms of making it to market first, assuming that the Phase III Oral-lyn trial has produced positive results.
Investors have heard all about AE-37 for the past few months, but nothing about Oral-lyn, so it's time for Generex to sit or get off the pot.
All eyes will be on Wednesday, and last week's trading actions shows that there is quite some anticipation for this event.
Disclosure: Long GNBT.